- Home
- ACIU vs PBPB Comparison
ACIU vs PBPB Comparison
Compare ACIU & PBPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- PBPB
- Stock Information
- Founded
- ACIU 2003
- PBPB 1977
- Country
- ACIU Switzerland
- PBPB United States
- Employees
- ACIU N/A
- PBPB N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- PBPB Restaurants
- Sector
- ACIU Health Care
- PBPB Consumer Discretionary
- Exchange
- ACIU Nasdaq
- PBPB Nasdaq
- Market Cap
- ACIU 332.4M
- PBPB 313.6M
- IPO Year
- ACIU 2016
- PBPB 2013
- Fundamental
- Price
- ACIU $3.15
- PBPB $10.01
- Analyst Decision
- ACIU Strong Buy
- PBPB Strong Buy
- Analyst Count
- ACIU 2
- PBPB 3
- Target Price
- ACIU $12.00
- PBPB $15.67
- AVG Volume (30 Days)
- ACIU 153.3K
- PBPB 152.1K
- Earning Date
- ACIU 11-05-2024
- PBPB 11-07-2024
- Dividend Yield
- ACIU N/A
- PBPB N/A
- EPS Growth
- ACIU N/A
- PBPB 641.95
- EPS
- ACIU N/A
- PBPB 1.25
- Revenue
- ACIU $48,505,404.00
- PBPB $471,719,000.00
- Revenue This Year
- ACIU $85.33
- PBPB N/A
- Revenue Next Year
- ACIU $80.69
- PBPB $3.71
- P/E Ratio
- ACIU N/A
- PBPB $8.01
- Revenue Growth
- ACIU 4097200.00
- PBPB N/A
- 52 Week Low
- ACIU $2.25
- PBPB $6.28
- 52 Week High
- ACIU $5.14
- PBPB $14.36
- Technical
- Relative Strength Index (RSI)
- ACIU 45.68
- PBPB 56.62
- Support Level
- ACIU $3.10
- PBPB $9.96
- Resistance Level
- ACIU $3.25
- PBPB $10.64
- Average True Range (ATR)
- ACIU 0.14
- PBPB 0.30
- MACD
- ACIU -0.02
- PBPB -0.07
- Stochastic Oscillator
- ACIU 13.16
- PBPB 43.24
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.